| 0.669 -0.039 (-5.51%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.88  |
1-year : | 2.58 |
| Resists | First : | 1.61 |
Second : | 2.21 |
| Pivot price | 0.87 |
|||
| Supports | First : | 0.63 | Second : | 0.53 |
| MAs | MA(5) : | 0.69 |
MA(20) : | 1.14 |
| MA(100) : | 1.94 |
MA(250) : | 4.79 |
|
| MACD | MACD : | -0.4  |
Signal : | -0.4 |
| %K %D | K(14,3) : | 4 |
D(3) : | 4.4 |
| RSI | RSI(14): 23.9 |
|||
| 52-week | High : | 27.39 | Low : | 0.63 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AEMD ] has closed above bottom band by 27.8%. Bollinger Bands are 22.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.73 - 0.73 | 0.73 - 0.73 |
| Low: | 0.66 - 0.66 | 0.66 - 0.67 |
| Close: | 0.66 - 0.67 | 0.67 - 0.68 |
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Mon, 13 Jul 2026
Aethlon Medical reports second cohort results from cancer study - Investing.com UK
Mon, 13 Jul 2026
Aethlon Medical (AEMD) Slides 5.4% as Pressure Mounts Near Key Support Level - Earnings Beat Stocks - dars.gov.et
Mon, 13 Jul 2026
Aethlon Medical advances Hemopurifier oncology study to third cohort - grafa.com
Mon, 13 Jul 2026
Experimental cancer filter shows repeat immune and tumor-signal shifts in small Australian study - Stock Titan
Sat, 11 Jul 2026
Aethlon Medical Inc. (AEMD) Q2 2026 Earnings: Narrower Loss Exceeds Expectations - Pretax Income Report - DonanımHaber
Fri, 10 Jul 2026
AETHLON MEDICAL INC (AEMD) Stock Chart - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 5.8 (%) |
| Shares Short | 218 (K) |
| Shares Short P.Month | 330 (K) |
| EPS | -10.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -66.6 % |
| Return on Equity (ttm) | -142.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.07 |
| PEG Ratio | 0 |
| Price to Book value | 0.21 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|